Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

Open in Screener

BIIB

Biogen Inc

Mar 12 • 11:41AM ET

140.85

Dollar change -2.81
Percentage change -1.96	%

Healthcare • Drug Manufacturers - General • USA • NASD

Peers: VRTX GILD REGN AMGN MRK PFE BMY LLY JNJ NBIX

| Held by: VTI VOO QQQ VO COWZ SPY IVV VTV XLV RSP

Index	NDX, S&P 500	P/E	12.60	EPS (ttm)	11.18	Insider Own	0.52%	Shs Outstand	145.80M	Perf Week	-2.03%
Market Cap	20.62B	Forward P/E	8.88	EPS next Y	15.86	Insider Trans	-1.15%	Shs Float	145.61M	Perf Month	-1.19%
Income	1.63B	PEG	-	EPS next Q	3.56	Inst Own	91.01%	Short Float	2.55%	Perf Quarter	-10.73%
Sales	9.27B	P/S	2.22	EPS this Y	-3.07%	Inst Trans	2.17%	Short Ratio	2.37	Perf Half Y	-29.32%
Book/sh	114.65	P/B	1.23	EPS next Y	-0.68%	ROA	5.95%	Short Interest	3.72M	Perf Year	-36.91%
Cash/sh	16.23	P/C	8.68	EPS next 5Y	-0.06%	ROE	10.36%	52W Range	128.51 - 238.00	Perf YTD	-7.89%
Dividend Est.	-	P/FCF	7.57	EPS past 5Y	-18.66%	ROI	7.56%	52W High	-40.82%	Beta	0.03
Dividend TTM	-	Quick Ratio	0.90	Sales past 5Y	-5.94%	Gross Margin	67.37%	52W Low	9.60%	ATR (14)	4.87
Dividend Ex-Date	-	Current Ratio	1.35	EPS Y/Y TTM	39.71%	Oper. Margin	22.49%	RSI (14)	45.67	Volatility	4.52% 3.52%
Employees	7605	Debt/Eq	0.40	Sales Y/Y TTM	-1.60%	Profit Margin	17.61%	Recom	2.11	Target Price	194.25
Option/Short	Yes / Yes	LT Debt/Eq	0.29	EPS Q/Q	6.56%	Payout	0.00%	Rel Volume	1.15	Prev Close	143.66
Sales Surprise	1.93%	EPS Surprise	3.26%	Sales Q/Q	1.66%	Earnings	Feb 12 BMO	Avg Volume	1.57M	Price	140.85
SMA20	-0.35%	SMA50	-2.24%	SMA200	-23.01%	Trades		Volume	669,011	Change	-1.96%

Date	Action	Analyst	Rating Change	Price Target Change
Feb-11-25	Initiated	Bernstein	Mkt Perform	$160
Jan-02-25	Downgrade	Piper Sandler	Overweight → Neutral	$315 → $138
Dec-20-24	Downgrade	BMO Capital Markets	Outperform → Market Perform	$230 → $164
Dec-16-24	Downgrade	Stifel	Buy → Hold	$175
Dec-10-24	Resumed	BofA Securities	Neutral	$178
Dec-09-24	Downgrade	Jefferies	Buy → Hold	$250 → $180
Nov-18-24	Downgrade	Needham	Buy → Hold
Nov-15-24	Initiated	Wolfe Research	Peer Perform
Nov-14-24	Initiated	Citigroup	Neutral	$190
Oct-31-24	Downgrade	Morgan Stanley	Overweight → Equal-Weight	$285 → $204
Oct-10-24	Resumed	Raymond James	Mkt Perform
Feb-14-24	Reiterated	Needham	Buy	$305 → $300
Feb-14-24	Downgrade	Wells Fargo	Overweight → Equal Weight	$315 → $240
Jan-24-24	Downgrade	UBS	Buy → Neutral	$311 → $276
Dec-20-23	Resumed	Cantor Fitzgerald	Overweight	$311
Dec-07-23	Upgrade	Raymond James	Mkt Perform → Outperform	$283
Sep-06-23	Initiated	HSBC Securities	Buy	$360
Jul-27-23	Initiated	Scotiabank	Sector Outperform	$327
Jul-24-23	Reiterated	UBS	Buy	$346 → $335
May-01-23	Upgrade	Guggenheim	Neutral → Buy	$270 → $350

Show Previous Ratings

Today 07:47AM	Biogen begins dosing in trial of felzartamab for kidney transplant patients with AMR (Clinical Trials Arena)
Mar-11-25 07:30AM	Biogen Initiates Phase 3 Study of Felzartamab for the Treatment of Late Antibody-Mediated Rejection (AMR) in Kidney Transplant Patients (GlobeNewswire)
Mar-04-25 01:49PM	Is Eli Lilly Stock A Buy As It Plays Ball With Trump To The Tune Of $27 Billion? (Investor's Business Daily)
12:02PM	Tariffs Send Investors to Safety of Food, Drug and Utility Stocks (The Wall Street Journal)
02:11AM	New tau candidates, including an RNA therapy from Voyager, drive a multi-pronged Alzheimers approach (Pharma Voice)
04:02AM	Loading…
Mar-03-25 04:02AM	3 Reasons BIIB is Risky and 1 Stock to Buy Instead (StockStory)
Feb-28-25 08:23AM	The Committee for Medicinal Products for Human Use (CHMP) Reaffirms Positive Opinion for Lecanemab in Early Alzheimer's Disease (PR Newswire)
Feb-25-25 12:19PM	Biogen Inc. (BIIB): Among the Stocks That Will Go to The Moon According to Analysts (Insider Monkey)
Feb-24-25 12:39PM	NHS England's Transition From Biogen's Drug To Sandoz's Biosimilar Sparks Alarm As Multiple Sclerosis Patients Report Severe Effects (Benzinga)
Feb-22-25 11:47PM	Biogen Inc. (BIIB): Among the Cheap Pharmaceutical Stocks to Buy According to Analysts (Insider Monkey)
Feb-19-25 06:55AM	Biogen and Stoke Therapeutics to commercialise Dravet syndrome treatment (Pharmaceutical Technology)
Feb-18-25 01:32PM	Biogen Strengthens Pipeline With Stoke Therapeutic's Dravet Syndrome Candidate Via Multi-Million Dollar Deal (Benzinga)
08:00AM	Biogen and Stoke Therapeutics Enter into Collaboration to Develop and Commercialize Zorevunersen for the Treatment of Dravet Syndrome, a Rare Genetic Epilepsy Associated with Refractory Seizures and Neurodevelopmental Impairments (Business Wire)
07:25AM	Biogen buys rights to Stokes rare epilepsy drug (BioPharma Dive)
Feb-13-25 02:30PM	Leqembi And Skyclarys Expected To Drive Biogen's Future Growth: Analysts (Benzinga)
10:43AM	Loading…
10:43AM	Sage Therapeutics price target lowered to $12 from $14 at Scotiabank (TipRanks)
10:33AM	Neumora shakes up its C-suite; Biogen cuts early-stage pipeline (BioPharma Dive)
07:33AM	Royalty Pharma pays $250m for rights to Biogens lupus drug (Pharmaceutical Technology)
02:08AM	Biogen Inc (BIIB) Q4 2024 Earnings Call Highlights: Strong EPS Growth Amid Revenue Challenges (GuruFocus.com)
12:04AM	Analyst Report: Biogen Inc. (Morningstar Research)
Feb-12-25 11:30PM	Q4 2024 Biogen Inc Earnings Call (Thomson Reuters StreetEvents)
04:18PM	Biogen Hammered As Lackluster Guidance Drags On Fourth-Quarter Beat (Investor's Business Daily)
01:30PM	Biogen (BIIB) Q4 2024 Earnings Call Transcript (Motley Fool)
01:13PM	Vertiv, Biogen, Super Micro Computer: Market Minute (Yahoo Finance Video)
10:49AM	Q4 2024 SAGE Therapeutics Inc Earnings Call (Thomson Reuters StreetEvents)
09:51AM	Biogen expects 2025 profit decline despite strong Q4 (Yahoo Finance Video)
09:39AM	Biogen Q4 Earnings: Revenue And EPS Beat, Warns Lower 2025 Revenue, Inks R&D Funding Pact With Royalty Pharma (Benzinga)
09:30AM	Biogen (BIIB) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates (Zacks)
08:10AM	Biogen Inc. (BIIB) Q4 Earnings and Revenues Surpass Estimates (Zacks)
07:41AM	Biogens (NASDAQ:BIIB) Q4 Sales Top Estimates (StockStory)
06:47AM	Loading…
06:47AM	Biogen expects lower 2025 profit as multiple sclerosis drugs face fierce competition (Reuters)
06:45AM	Why Investors Might Hammer Biogen Despite Its Earnings Beat (Investor's Business Daily)
Feb-11-25 04:28PM	5 Struggling Stocks That Might Be Buys (Barrons.com)
01:56PM	What To Expect From Alzheimer's Drugmaker Biogen's Q4 Earnings On Wednesday? (Benzinga)
09:49AM	Bernstein starts Biogen at market-perform, notes near term uncertainty (Investing.com)
08:01AM	Biogen (BIIB) Reports Earnings Tomorrow: What To Expect (StockStory)
Feb-08-25 09:20AM	Why Biogen Inc. (BIIB) Is Among the Best Healthcare Stocks To Buy According to Analysts (Insider Monkey)
Feb-07-25 09:15AM	Seeking Clues to Biogen (BIIB) Q4 Earnings? A Peek Into Wall Street Projections for Key Metrics (Zacks)
07:32AM	Genentech eyes lupus market for Gazyva with positive Phase III data readout (Pharmaceutical Technology)
Feb-05-25 10:00AM	Biogen Inc. (BIIB) Reports Next Week: Wall Street Expects Earnings Growth (Zacks)
08:16AM	Lillys investigational Alzheimers to be investigated in prevention trial (Clinical Trials Arena)
Feb-02-25 08:12AM	Why Are Analysts Bullish on Biogen Inc. (BIIB) Now? (Insider Monkey)
Jan-31-25 06:30AM	Update on Regulatory Review of Lecanemab for Early Alzheimer's Disease in the European Union (GlobeNewswire)
Jan-29-25 12:10PM	Will Biogen (BIIB) Beat Estimates Again in Its Next Earnings Report? (Zacks)
Jan-28-25 07:28AM	Sage rejects Biogens $469m takeover bid (Pharmaceutical Technology)
Jan-27-25 12:40PM	Sage rebuffs Biogen bid to take it over (BioPharma Dive)
09:28AM	Sage rejects Biogen's $469 million takeover offer, says offer undervalues company (Reuters)
07:12AM	Eisai and Biogens Leqembi sBLA set for Alzheimers maintenance dosing (Pharmaceutical Technology)
07:05AM	FDA clears monthly dosing of Alzheimers drug Leqembi (BioPharma Dive)
Jan-26-25 06:38PM	US FDA OKs monthly maintenance dosing for Eisai/Biogen's Alzheimer's drug (Reuters)
06:33PM	FDA Approves LEQEMBI (lecanemab-irmb) IV Maintenance Dosing for the Treatment of Early Alzheimer's Disease (GlobeNewswire)
Jan-23-25 12:06PM	Biogens higher dose Spinraza under review by US and EU regulators (Pharmaceutical Technology)
09:46AM	Eli Lilly Stock Has Tumbled 23% Since Its August High. Is It A Buy Or A Sell? (Investor's Business Daily)
07:30AM	FDA and EMA Accept Applications for Higher Dose Regimen of Nusinersen in SMA (GlobeNewswire)
Jan-22-25 12:03PM	Downside risk from talc lawsuit, Stelara generic competition is 'manageable': JNJ CFO Joe Wolk (Yahoo Finance)
Jan-21-25 06:05AM	Bain Capital in Talks to Buy Mitsubishi Tanabe Pharma (The Wall Street Journal)
Jan-15-25 06:52AM	At JPM, Biogen CEO tries to take down the deal temperature (BioPharma Dive)
06:26AM	Federal watchdog cites concerns with FDAs accelerated approval process (BioPharma Dive)
Jan-14-25 06:00PM	Biogen CEO sees no burning need for more acquisitions (Reuters)
09:41AM	Sage Therapeutics takeover bid undervalues Zurzuvae, says Truist (TipRanks)
09:40AM	Biogen bid for Sage does not change narrative, says BMO Capital (TipRanks)
09:04AM	FDA To Review Under the Skin Weekly Autoinjector For Biogen/Eisai's Alzheimer's Drug Leqembi (Benzinga)
08:06AM	Eisai and Biogens subcutaneous Leqembi set for FDA review (Pharmaceutical Technology)
Jan-13-25 07:05PM	FDA Accepts LEQEMBI (lecanemab-irmb) Biologics License Application for Subcutaneous Maintenance Dosing for the Treatment of Early Alzheimer's Disease (GlobeNewswire)
03:12PM	Biogen proposes acquisition of partner Sage Therapeutics (Pharmaceutical Technology)
11:57AM	Top Stock Movers Now: Moderna, Macy's, Valero Energy, and More (Investopedia)
09:56AM	Biogen Wants to Buy Its Partner Sage for Almost No Premium (Barrons.com)
09:51AM	Sage Therapeutics Stock Soars as Biogen Makes Unsolicited Takeover Bid (Investopedia)
09:38AM	Why Is Depression-Focused Sage Therapeutics Stock Surging Higher On Monday? (Benzinga)
07:24AM	Sage Therapeutics Stock Rockets 35% Higher After Takeover Bid From Biogen (Barrons.com)
07:07AM	Biogens cold and calculated offer to buy Sage receives a mixed reaction on Wall Street (BioPharma Dive)
Jan-10-25 06:49PM	Sage Therapeutics Confirms Receipt of Unsolicited Nonbinding Acquisition Proposal from Biogen (Business Wire)
06:37PM	Biogen proposes to buy remaining stake in Sage in $442 million deal (Reuters)
09:02AM	Heres Why ClearBridge Growth Strategy Sold Biogen (BIIB) (Insider Monkey)
06:43AM	Pfizers PD-1 drug succeeds; AbbVie writes down $3.5B in Cerevel assets (BioPharma Dive)
06:25AM	Alzheimers Drugs Eyed as Next Big Obesity-Like Opportunity (Bloomberg)
Jan-09-25 08:00AM	Is Eli Lilly Stock A Buy Or A Sell After Its Weight-Loss Drug Scores A Major Victory? (Investor's Business Daily)
Jan-08-25 04:40PM	Has Jim Cramer Lost Faith in Biogen Inc. (BIIB)s Struggles with Alzheimers and MS Challenges? (Insider Monkey)
Jan-04-25 07:45AM	These Were the 5 Worst-Performing Stocks in the Nasdaq-100 in 2024 (Motley Fool)
Jan-02-25 12:03PM	Is Eli Lilly Stock A Buy After FDA Pushes Back On Compounded Knockoffs? (Investor's Business Daily)
09:25AM	Piper Sandler downgrades Biogen, slashes PT by $177 amid transition challenges (Investing.com)
Jan-01-25 09:40AM	Why Biogen Inc. (BIIB) is a Top Value Stock for the Long-Term (Zacks)
09:37AM	The 5 worst performing stocks on the Nasdaq 100 in 2024 (TheStreet)
Dec-28-24 04:49PM	Biogen Inc. (BIIB): Among the Cheap Healthcare Stocks to Buy Heading Into 2025 (Insider Monkey)
Dec-23-24 05:07AM	Biogen Faces Multiple Analyst Downgrades in December 2024 (GuruFocus.com)
Dec-20-24 09:44AM	BMO cuts rating on Merck and Biogen, on lack of near term catalyst (Investing.com)
Dec-16-24 01:16PM	Stifel downgrades Biogen on slow Alzheimers drug launch, uncertainty ahead (Investing.com)
10:26AM	Netflix, Ford, Biogen: Trending tickers (Yahoo Finance Video)
Dec-13-24 08:00AM	CMS says private Medicare plans cant automatically deny Biogens ALS drug (BioPharma Dive)
Dec-11-24 07:10AM	Biogen reinstated with a Neutral at BofA (TipRanks)
Dec-09-24 01:44PM	Biogen Downgraded On Pipeline Setbacks And Leqembi Sales Slowdown (Benzinga)
12:27PM	Biogen cut at Jefferies as '2025 has a tough setup' (Investing.com)
Dec-05-24 08:30AM	GeneDx to Expand Access to Exome Testing for Pediatric Epilepsy Patients with New Partners (Business Wire)
Dec-04-24 06:31PM	'LEQEMBI' (Lecanemab) Approved for the Treatment of Early Alzheimer's Disease in Mexico (PR Newswire)
Dec-02-24 07:44AM	Analyst Report: Biogen Inc. (Morningstar Research)
Nov-28-24 06:08AM	Why Biogen Inc. (BIIB) is One of the Cheapest Stocks to Buy on Robinhood? (Insider Monkey)
Nov-27-24 07:31PM	'LEQEMBI' (Lecanemab) for the Treatment of Alzheimer's Disease Launched in South Korea (PR Newswire)
09:15AM	Why Is Biogen Inc. (BIIB) Among the Worst Performing Healthcare Stocks in 2024? (Insider Monkey)
Nov-26-24 02:23PM	Eli Lilly Pops After Biden Proposes Medicare Cover Obesity Drugs. Is Lilly Stock A Buy? (Investor's Business Daily)
Nov-22-24 11:00AM	Is Eli Lilly Stock A Sell After Kennedy-Tied Woes Rankled Shares? (Investor's Business Daily)

Biogen, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases. Its products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for the treatment of MS, SPINRAZA for the treatment of SMA, ADUHELM for the treatment of Alzheimer's disease, and FUMADERM for the treatment of severe plaque psoriasis. The company was founded by Charles Weissmann, Heinz Schaller, Kenneth Murray, Walter Gilbert, and Phillip Allen Sharp in 1978 and is headquartered in Cambridge, MA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
SHERWIN STEPHEN A	Director	Mar 07 '25	Sale	150.02	8,760	1,314,142	11,318	Mar 10 04:09 PM
STEPHEN A SHERWIN	Director	Mar 07 '25	Proposed Sale	147.37	8,760	1,290,961		Mar 07 04:18 PM
Singhal Priya	Head of Development	Feb 10 '25	Option Exercise	0.00	1,212	0	9,423	Feb 12 05:48 PM
Murphy Nicole	Head of Pharm Ops and Tech	Feb 10 '25	Option Exercise	0.00	2,272	0	14,725	Feb 12 05:47 PM
MCDONNELL MICHAEL R	EVP, Chief Financial Officer	Feb 10 '25	Option Exercise	0.00	3,257	0	25,712	Feb 12 05:46 PM
Kramer Robin	Chief Accounting Officer	Feb 10 '25	Option Exercise	0.00	834	0	8,257	Feb 12 05:44 PM
Gregory Ginger	EVP, Human Resources	Feb 10 '25	Option Exercise	0.00	2,159	0	18,232	Feb 12 05:43 PM
ALEXANDER SUSAN H	EVP Chief Legal Officer	Feb 10 '25	Option Exercise	0.00	2,575	0	37,072	Feb 12 05:42 PM
Izzar Rachid	Head of Global Product Strat.	Feb 10 '25	Option Exercise	0.00	1,515	0	8,998	Feb 12 05:40 PM
Izzar Rachid	Head of Global Product Strat.	Feb 07 '25	Option Exercise	0.00	3,844	0	7,860	Feb 11 09:52 PM
MCDONNELL MICHAEL R	EVP, Chief Financial Officer	Feb 07 '25	Option Exercise	0.00	4,551	0	23,171	Feb 10 06:59 PM
Viehbacher Christopher	President and CEO	Feb 07 '25	Option Exercise	0.00	9,008	0	16,008	Feb 10 06:55 PM
Grogan Jane	Head of Research	Feb 07 '25	Option Exercise	0.00	1,385	0	1,876	Feb 10 06:52 PM
Keeney Adam	Head of Corporate Development	Feb 07 '25	Option Exercise	0.00	1,801	0	2,463	Feb 10 06:51 PM
Kramer Robin	Chief Accounting Officer	Feb 07 '25	Option Exercise	0.00	1,491	0	7,667	Feb 10 06:48 PM
Murphy Nicole	Head of Pharm Ops and Tech	Feb 07 '25	Option Exercise	0.00	4,042	0	13,056	Feb 10 06:47 PM
Singhal Priya	Head of Development	Feb 07 '25	Option Exercise	0.00	2,216	0	8,892	Feb 10 06:45 PM
Gregory Ginger	EVP, Human Resources	Feb 07 '25	Option Exercise	0.00	3,436	0	16,633	Feb 10 06:44 PM
ALEXANDER SUSAN H	EVP Chief Legal Officer	Feb 07 '25	Option Exercise	0.00	4,130	0	35,088	Feb 10 06:42 PM
Singhal Priya	Head of Development	Jan 31 '25	Option Exercise	0.00	1,828	0	7,254	Feb 03 06:02 PM
Singhal Priya	Head of Development	Dec 06 '24	Option Exercise	0.00	426	0	5,742	Dec 09 04:57 PM
Singhal Priya	Head of Development	Dec 09 '24	Sale	157.21	110	17,293	5,426	Dec 09 04:57 PM
Kramer Robin	Chief Accounting Officer	Dec 06 '24	Option Exercise	0.00	351	0	6,578	Dec 09 04:56 PM
Singhal Priya	Officer	Dec 09 '24	Proposed Sale	157.21	110	17,293		Dec 09 10:33 AM
Grogan Jane	Head of Research	Nov 01 '24	Option Exercise	0.00	695	0	695	Nov 04 04:39 PM
Singhal Priya	Head of Development	Aug 30 '24	Option Exercise	0.00	1,668	0	6,554	Sep 05 06:00 AM
Singhal Priya	Head of Development	Sep 03 '24	Sale	204.22	431	88,019	5,316	Sep 05 06:00 AM
Singhal Priya	Officer	Sep 03 '24	Proposed Sale	204.22	431	88,019		Sep 03 01:00 PM
Keeney Adam	Head of Corporate Development	May 01 '24	Option Exercise	0.00	938	0	938	May 03 08:00 PM
Singhal Priya	Head of Development	Apr 02 '24	Sale	213.09	93	19,817	4,886	Apr 03 08:24 PM
Murphy Nicole	Head of Pharm Ops and Tech	Apr 01 '24	Option Exercise	0.00	240	0	9,751	Apr 03 08:11 PM

Dollar change +0.88
Percentage change 0.82	%

NBIX Neurocrine Biosciences, Inc daily Stock Chart

Peers: VRTX REGN BIIB GILD INCY ALNY EXEL IONS SAGE ACAD

| Held by: VTI VB IJH VXF VBK XBI MDY USMV IJK IBB

Index	-	P/E	32.85	EPS (ttm)	3.29	Insider Own	2.88%	Shs Outstand	99.40M	Perf Week	-5.05%
Market Cap	10.78B	Forward P/E	17.44	EPS next Y	6.20	Insider Trans	-8.86%	Shs Float	96.83M	Perf Month	-9.01%
Income	341.30M	PEG	0.86	EPS next Q	0.83	Inst Own	94.18%	Short Float	3.33%	Perf Quarter	-15.64%
Sales	2.36B	P/S	4.58	EPS this Y	28.07%	Inst Trans	2.22%	Short Ratio	2.47	Perf Half Y	-10.39%
Book/sh	26.05	P/B	4.15	EPS next Y	47.11%	ROA	9.51%	Short Interest	3.23M	Perf Year	-22.35%
Cash/sh	10.79	P/C	10.02	EPS next 5Y	38.09%	ROE	14.16%	52W Range	105.18 - 157.98	Perf YTD	-20.81%
Dividend Est.	-	P/FCF	19.34	EPS past 5Y	53.47%	ROI	11.21%	52W High	-31.57%	Beta	0.35
Dividend TTM	-	Quick Ratio	3.28	Sales past 5Y	24.80%	Gross Margin	97.56%	52W Low	2.78%	ATR (14)	3.85
Dividend Ex-Date	Dec 29, 1995	Current Ratio	3.40	EPS Y/Y TTM	33.67%	Oper. Margin	24.75%	RSI (14)	28.36	Volatility	3.01% 3.10%
Employees	1800	Debt/Eq	0.19	Sales Y/Y TTM	24.81%	Profit Margin	14.49%	Recom	1.54	Target Price	165.08
Option/Short	Yes / Yes	LT Debt/Eq	0.18	EPS Q/Q	-30.61%	Payout	0.00%	Rel Volume	0.62	Prev Close	107.22
Sales Surprise	-0.28%	EPS Surprise	-37.73%	Sales Q/Q	21.84%	Earnings	Feb 06 AMC	Avg Volume	1.31M	Price	108.10
SMA20	-5.85%	SMA50	-17.55%	SMA200	-17.54%	Trades		Volume	300,209	Change	0.82%

Date	Action	Analyst	Rating Change	Price Target Change
Feb-11-25	Initiated	Deutsche Bank	Hold	$138
Oct-10-24	Resumed	Raymond James	Outperform	$155
Aug-29-24	Upgrade	Piper Sandler	Neutral → Overweight	$131 → $159
Apr-24-24	Upgrade	Wells Fargo	Equal Weight → Overweight	$140 → $170
Dec-13-23	Resumed	Citigroup	Neutral	$127
Dec-12-23	Initiated	Deutsche Bank	Buy	$136
Oct-24-23	Resumed	Cantor Fitzgerald	Overweight	$135 → $140
Aug-21-23	Reiterated	Mizuho	Neutral	$112 → $113
Jul-24-23	Upgrade	SVB Securities	Market Perform → Outperform	$115 → $125
Jul-06-23	Upgrade	BMO Capital Markets	Underperform → Market Perform	$91 → $96
May-04-23	Upgrade	Guggenheim	Neutral → Buy	$145
Mar-30-23	Upgrade	Canaccord Genuity	Hold → Buy	$124 → $132
Mar-03-23	Upgrade	Evercore ISI	In-line → Outperform	$130
Feb-03-23	Upgrade	Morgan Stanley	Equal-Weight → Overweight	$120 → $130
Nov-14-22	Downgrade	Evercore ISI	Outperform → In-line	$140 → $130
Oct-11-22	Initiated	UBS	Buy	$136
Sep-26-22	Initiated	Wells Fargo	Equal Weight	$110
Jun-06-22	Resumed	Jefferies	Buy	$126 → $112
Mar-03-22	Downgrade	Piper Sandler	Overweight → Neutral	$114 → $94
Feb-25-22	Upgrade	Goldman	Neutral → Buy	$115

Show Previous Ratings

Mar-11-25 04:01PM	Neurocrine Biosciences to Present at the Stifel 2025 Virtual CNS Forum (PR Newswire)
Mar-06-25 07:26AM	Neurocrine Biosciences initiates trial of VMAT2 inhibitor in healthy adults (Clinical Trials Arena)
Mar-05-25 08:30AM	Neurocrine Biosciences Announces Initiation of Phase 1 Clinical Study Evaluating NBI-1140675, a Second-Generation VMAT2 Inhibitor, in Healthy Adults (PR Newswire)
Feb-27-25 04:05PM	Neurocrine Biosciences Reports Patient-Reported Outcome Data from KINECT-PRO Study for INGREZZA (valbenazine) Capsules in Tardive Dyskinesia: Significant and Clinically Meaningful Improvements in Functionality and Quality of Life Measures (PR Newswire)
Feb-25-25 04:01PM	Neurocrine Biosciences to Present at Upcoming Investor Conferences in March (PR Newswire)
03:11PM	Loading…
Feb-21-25 03:11PM	Is Neurocrine Biosciences (NBIX) One of the Best Fast Growth Stock to Buy Right Now? (Insider Monkey)
08:00AM	Neurocrine Biosciences Board of Directors Authorizes $500 Million Share Repurchase Program (PR Newswire)
Feb-18-25 04:08PM	Neurocrine (NBIX): Among Top Insider Stock Buys And Sells In January (Insider Monkey)
Feb-10-25 06:18PM	Why Neurocrine Biosciences Stock Sank Today (Motley Fool)
08:32AM	Why Neurocrine Biosciences Inc. (NBIX) Crashed Last Week (Insider Monkey)
Feb-08-25 11:01AM	Here's Why Neurocrine Biosciences Inc. (NBIX) Crashed on Friday (Insider Monkey)
Feb-07-25 04:43PM	Neurocrine Crumbles On Lackluster Guidance For Its Bread-And-Butter Drug (Investor's Business Daily) -18.53%
04:25PM	These Stocks Moved the Most Today: Amazon, Tesla, Uber, Affirm, Pinterest, Take-Two, Expedia, Bill, e.l.f. Beauty, and More (Barrons.com)
03:15PM	These Stocks Are Moving the Most Today: Amazon, Tesla, Uber, Affirm, Pinterest, Take-Two, Expedia, Bill, e.l.f. Beauty, and More (Barrons.com)
01:05PM	Why Is Neurocrine Biosciences Stock Trading Lower On Friday? (Benzinga)
08:15AM	Loading…
08:15AM	Q4 2024 Neurocrine Biosciences Inc Earnings Call (Thomson Reuters StreetEvents)
02:23AM	Neurocrine Biosciences Inc (NBIX) Q4 2024 Earnings Call Highlights: Record INGREZZA Growth and ... (GuruFocus.com)
Feb-06-25 05:15PM	Neurocrine Biosciences (NBIX) Q4 Earnings and Revenues Lag Estimates (Zacks)
04:27PM	Neurocrine: Q4 Earnings Snapshot (Associated Press Finance)
04:01PM	Neurocrine Biosciences Reports Fourth Quarter and Fiscal 2024 Financial Results and Provides Financial Expectations for 2025 (PR Newswire)
Feb-04-25 12:47PM	Neurocrine Biosciences, Inc. (NBIX): Among the Best Low Risk High Growth Stocks To Invest In Now (Insider Monkey)
09:15AM	Neurocrine (NBIX) Q4 Earnings on the Horizon: Analysts' Insights on Key Performance Measures (Zacks)
Jan-30-25 04:01PM	Neurocrine Biosciences Announces Conference Call and Webcast of Fourth Quarter and Year-End 2024 Financial Results (PR Newswire)
Jan-29-25 10:01AM	Neurocrine Biosciences (NBIX) Earnings Expected to Grow: What to Know Ahead of Q4 Release (Zacks)
Jan-28-25 10:24AM	Neurocrine Obtains Exclusive Rights For Depression Drug, Takeda Reacquires Japan Rights (Benzinga)
08:30AM	Neurocrine Biosciences Announces Initiation of Phase 3 Registrational Program for Osavampator as an Adjunctive Therapy for the Treatment of Major Depressive Disorder in Adults (PR Newswire)
Jan-27-25 04:05PM	Neurocrine Biosciences Announces Amendment to Strategic Collaboration with Takeda to Develop and Commercialize Osavampator (formerly NBI-1065845/TAK-653) (PR Newswire)
Jan-23-25 04:05PM	Andrew Ratz, Ph.D., Joins Neurocrine Biosciences as Senior Vice President of Drug Development, Delivery and Device (PR Newswire)
Jan-21-25 04:05PM	Neurocrine Biosciences Announces Classic Congenital Adrenal Hyperplasia Supplement Published Today in The Journal of Clinical Endocrinology & Metabolism (PR Newswire)
Jan-08-25 08:30AM	Neurocrine Biosciences Announces Publication on Traditional Glucocorticoid Treatment in Classic Congenital Adrenal Hyperplasia in Expert Review of Endocrinology and Metabolism (PR Newswire)
08:30AM	Loading…
08:30AM	Neurocrine Biosciences Announces Publication on Traditional Glucocorticoid Treatment in Classic Congenital Adrenal Hyperplasia in Expert Review of Endocrinology & Metabolism (PR Newswire)
Jan-06-25 04:01PM	Neurocrine Biosciences to Present at the 43rd Annual J.P. Morgan Healthcare Conference (PR Newswire)
Dec-24-24 03:23PM	Neurocrine Biosciences Stock Sees RS Rating Upgrade (Investor's Business Daily)
Dec-20-24 08:00AM	Neurocrine Biosciences Announces Commercial Availability of CRENESSITY (crinecerfont) for Children and Adults With Classic Congenital Adrenal Hyperplasia (PR Newswire)
Dec-16-24 04:10PM	Neurocrine Jumps After Snagging FDA Approval For A First-In-Decades Drug (Investor's Business Daily) +5.01%
09:10AM	Neurocrine's Drug Gains FDA Nod As First Targeted Treatment For Certain Type Of Inherited Disorder, Analyst Highlights Blockbuster Potential (Benzinga)
Dec-13-24 07:00PM	Neurocrine Wins FDA Approval For Genetic Disorder Drug (Investor's Business Daily)
06:55PM	Neurocrine Biosciences Announces FDA Approval of CRENESSITY (crinecerfont), a First-in-Class Treatment for Children and Adults With Classic Congenital Adrenal Hyperplasia (PR Newswire)
Dec-02-24 01:55PM	Why Is Neurocrine Biosciences, Inc. (NBIX) Among the Best High Growth Healthcare Stocks to Invest In Now? (Insider Monkey)
Nov-30-24 04:31PM	Why Neurocrine Biosciences (NBIX) Is the Most Profitable Pharmaceutical Stock Right Now? (Insider Monkey)
Nov-26-24 04:01PM	Neurocrine Biosciences to Participate at Investor Conferences in December (PR Newswire)
Nov-07-24 08:30AM	Neurocrine Biosciences Presents New KINECT-HD Data Showing Consistent Efficacy Across 19 Subgroups and Improvements in Aspects of Emotional Health With INGREZZA (valbenazine) Capsules (PR Newswire)
Nov-05-24 04:01PM	Neurocrine Biosciences to Participate at Investor Conferences in November (PR Newswire)
Nov-04-24 08:30AM	Neurocrine Biosciences Presents Breadth of Data Demonstrating Holistic Improvements Over Time in Patients With Tardive Dyskinesia Following Treatment With INGREZZA (valbenazine) Capsules (PR Newswire)
08:25AM	Neurocrine Biosciences Presents New Data on INGREZZA (valbenazine) Capsules at Psych Congress 2024: Majority of Long-Term Study Participants Achieved Remission of Tardive Dyskinesia (PR Newswire)
Oct-31-24 03:04AM	Neurocrine Biosciences Inc (NBIX) Q3 2024 Earnings Call Highlights: Strong Sales and Strategic ... (GuruFocus.com)
01:09AM	Decoding Neurocrine Biosciences Inc (NBIX): A Strategic SWOT Insight (GuruFocus.com)
Oct-30-24 09:30AM	Neurocrine (NBIX) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates (Zacks) +7.01%
08:10AM	Neurocrine Biosciences (NBIX) Q3 Earnings Miss Estimates (Zacks)
07:07AM	Neurocrine: Q3 Earnings Snapshot (Associated Press Finance)
07:00AM	Neurocrine Biosciences Reports Third Quarter 2024 Financial Results and Raises 2024 INGREZZA Sales Guidance (PR Newswire)
Oct-23-24 10:56AM	Implied Volatility Surging for Neurocrine Biosciences (NBIX) Stock Options (Zacks)
10:01AM	Neurocrine Biosciences (NBIX) Earnings Expected to Grow: Should You Buy? (Zacks)
Oct-17-24 01:02PM	State Street Corp's Strategic Acquisition in Neurocrine Biosciences Inc (GuruFocus.com)
Oct-16-24 04:04PM	Is Neurocrine Biosciences, Inc. (NBIX) the Most Promising Biotech Stock According to Hedge Funds? (Insider Monkey)
Oct-09-24 04:01PM	Neurocrine Biosciences Announces Conference Call and Webcast of Third Quarter 2024 Financial Results (PR Newswire)
Sep-30-24 08:30AM	Neurocrine Biosciences Presents Interim Data Demonstrating Robust and Sustained Improvements in Chorea Associated With Huntington's Disease Through Week 104 Irrespective of Antipsychotic Use (PR Newswire)
Sep-19-24 04:01PM	Neurocrine Biosciences to Participate at the TD Cowen 4th Annual Novel Mechanisms in Neuropsychiatry Virtual Summit (PR Newswire)
Sep-14-24 07:25PM	Neurocrine Biosciences, Inc. (NBIX): Hedge Funds Are Bullish on This Aggressive Growth Stock (Insider Monkey)
Sep-13-24 04:32AM	Neurocrines Phase II schizophrenia trial fails to meet primary endpoint (Clinical Trials Arena)
Sep-12-24 04:05PM	Neurocrine Biosciences Provides Update on ERUDITE Phase 2 Data for Luvadaxistat in Adults with Cognitive Impairment Associated with Schizophrenia (PR Newswire)
Sep-10-24 04:01PM	Neurocrine Biosciences to Participate at the 2024 Cantor Global Healthcare Conference (PR Newswire)
Sep-02-24 10:53AM	Nxera wins $35m after Phase II schizophrenia trial success (Pharmaceutical Technology)
Aug-30-24 07:41AM	Why Neurocrine Biosciences Stock Was Tumbling This Week (Motley Fool)
Aug-29-24 01:22PM	Neurocrine Biosciences' Lower Dose Data Puts Its Schizophrenia Candidate In The Game, Analyst Upgrades Stock (Benzinga)
06:52AM	Neurocrine reports positive data from Phase II schizophrenia treatment trial (Clinical Trials Arena)
Aug-28-24 06:19PM	Here's Why a Handful of Pharmaceutical Stocks Rose Wednesday (Investopedia) -18.87%
04:28PM	Neurocrine Plummets 19% Does It Still Have A Shot At This 'Significant Market Opportunity?' (Investor's Business Daily)
04:05PM	Neurocrine Biosciences to Participate at Investor Conferences in September (PR Newswire)
11:16AM	As Regulators Gear Up To Decide On Bristol Myers' Schizophrenia Treatment, Neurocrine Biosciences' Data Disappoints Investors (Benzinga)
09:56AM	Neurocrine Stock Hammered After Schizophrenia Drug Lags Two Key Rivals (Investor's Business Daily)
08:17AM	Neurocrine Bio Dives As Schizophrenia Trial Results Lag Peers (Investor's Business Daily)
08:15AM	Neurocrines mixed schizophrenia data disappoint Wall Street (BioPharma Dive)
07:07AM	Nxera Pharma Notes Positive Phase 2 Data for Partnered Schizophrenia Candidate NBI-1117568 (GlobeNewswire)
07:00AM	Neurocrine Biosciences Reports Positive Phase 2 Data for NBI-1117568 in Adults with Schizophrenia (PR Newswire)
Aug-16-24 07:01PM	Insider Sale: Director William Rastetter Sells 14,250 Shares of Neurocrine Biosciences Inc (NBIX) (GuruFocus.com)
Aug-07-24 04:01PM	Neurocrine Biosciences to Present at the Canaccord Genuity 44th Annual Growth Conference (PR Newswire)
Aug-06-24 12:45PM	Is Neurocrine (NBIX) a Solid Growth Stock? 3 Reasons to Think "Yes" (Zacks)
Aug-02-24 06:39AM	Vir retreats from infectious disease; Vertex shelves AATD drugs (BioPharma Dive)
01:05AM	Decoding Neurocrine Biosciences Inc (NBIX): A Strategic SWOT Insight (GuruFocus.com)
Aug-01-24 10:00AM	Compared to Estimates, Neurocrine (NBIX) Q2 Earnings: A Look at Key Metrics (Zacks) +8.18%
08:06AM	Neurocrine Biosciences Raises 2024 INGREZZA Net Product Sales Guidance (RTT News)
08:05AM	Neurocrine Biosciences (NBIX) Lags Q2 Earnings Estimates (Zacks)
07:09AM	Neurocrine: Q2 Earnings Snapshot (Associated Press Finance)
07:00AM	Neurocrine Biosciences Reports Second Quarter 2024 Financial Results and Raises 2024 INGREZZA Sales Guidance (PR Newswire)
Jul-31-24 09:15AM	Insights Into Neurocrine (NBIX) Q2: Wall Street Projections for Key Metrics (Zacks)
Jul-25-24 10:02AM	Neurocrine Biosciences (NBIX) Earnings Expected to Grow: What to Know Ahead of Next Week's Release (Zacks)
Jul-18-24 08:30AM	Neurocrine Biosciences Launches INGREZZA SPRINKLE (valbenazine) Capsules to Ease Administration for Patients Experiencing Dysphagia or Difficulty Swallowing (PR Newswire)
Jul-12-24 08:38AM	Implied Volatility Surging for Neurocrine Biosciences (NBIX) Stock Options (Zacks)
Jul-11-24 04:01PM	Neurocrine Biosciences Announces Conference Call and Webcast of Second Quarter 2024 Financial Results (PR Newswire)
Jul-02-24 06:33AM	FDA grants priority review for Neurocrines crinecerfont NDAs (Pharmaceutical Technology)
Jul-01-24 07:30AM	Neurocrine Biosciences Announces U.S. FDA Accepts New Drug Applications and Grants Priority Review for Crinecerfont for Pediatric and Adult Patients with CAH (PR Newswire)
Jun-28-24 04:37PM	How Medicare drug price negotiations could hit pharma stocks (Yahoo Finance Video)
Jun-17-24 03:27PM	7 Breakthrough Biotech Stocks for a Shot of Portfolio Adrenaline (InvestorPlace)
Jun-14-24 02:34PM	Neurocrine Biosciences Stock Tops Milestone Amid New Drug Plans (Investor's Business Daily)
Jun-03-24 08:01AM	Neurocrine Biosciences Presented CAHtalyst Phase 3 Pediatric and Adult Studies, CAHtalog Registry and Disease- and Glucocorticoid-Related Comorbidities Data in CAH at ENDO 2024 (PR Newswire)
07:35AM	Neurocrine Biosciences Announces Publication of Primary CAHtalyst Pediatric Phase 3 Study Results of Crinecerfont for the Treatment of CAH in The New England Journal of Medicine (PR Newswire)
07:30AM	Neurocrine Biosciences Announces Publication of Primary CAHtalyst Adult Phase 3 Study Results of Crinecerfont for the Treatment of CAH in The New England Journal of Medicine (PR Newswire)
May-29-24 04:01PM	Neurocrine Biosciences to Participate at Investor Conferences in June (PR Newswire)
May-28-24 04:14PM	Neurocrine Biosciences Announces CEO Succession Plan (PR Newswire)

Neurocrine Biosciences, Inc. is a neuroscience-focused, biopharmaceutical company, which engages in the research and development, commercialization, and sale of pharmaceuticals for the treatment of neurological, neuroendocrine, and neuropsychiatric disorders. Its portfolio of products includes treatments for tardive dyskinesia, chorea associated with Huntington's disease, classic congenital adrenal hyperplasia (CAH), and endometriosis and uterine fibroids. The company was founded by Kevin C. Gorman and Wylie W. Vale in January 1992 and is headquartered in San Diego, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Cooke Julie	Chief Human Resources Officer	Feb 13 '25	Option Exercise	0.00	2,910	0	20,945	Feb 14 07:13 PM
Cooke Julie	Chief Human Resources Officer	Feb 13 '25	Sale	116.78	1,551	181,129	19,544	Feb 14 07:13 PM
GORMAN KEVIN CHARLES	Director	Feb 13 '25	Option Exercise	0.00	10,979	0	527,221	Feb 14 06:57 PM
GORMAN KEVIN CHARLES	Director	Feb 13 '25	Sale	116.69	5,844	681,914	521,618	Feb 14 06:57 PM
SHERWIN STEPHEN A	Director	Feb 13 '25	Sale	116.69	13,831	1,613,923	10,673	Feb 14 06:49 PM
ROBERTS EIRY	Chief Medical Officer	Feb 13 '25	Option Exercise	0.00	4,605	0	36,140	Feb 14 06:42 PM
ROBERTS EIRY	Chief Medical Officer	Feb 13 '25	Sale	116.85	1,718	200,742	34,252	Feb 14 06:42 PM
ROBERTS EIRY	Chief Medical Officer	Feb 14 '25	Sale	115.04	500	57,521	35,640	Feb 14 06:42 PM
Onyia Jude	Chief Scientific Officer	Feb 13 '25	Option Exercise	0.00	5,407	0	19,536	Feb 14 06:35 PM
Onyia Jude	Chief Scientific Officer	Feb 13 '25	Sale	116.79	2,879	336,239	16,846	Feb 14 06:35 PM
Lippoldt Darin	Chief Legal Officer	Feb 13 '25	Option Exercise	0.00	4,100	0	44,491	Feb 14 06:26 PM
Lippoldt Darin	Chief Legal Officer	Feb 13 '25	Sale	116.75	2,184	254,992	42,474	Feb 14 06:26 PM
Gano Kyle	Chief Executive Officer	Feb 13 '25	Option Exercise	0.00	4,807	0	141,113	Feb 14 06:20 PM
Gano Kyle	Chief Executive Officer	Feb 13 '25	Sale	116.85	2,558	298,908	138,872	Feb 14 06:20 PM
Delaet Ingrid	Chief Regulatory Officer	Feb 13 '25	Option Exercise	0.00	2,759	0	5,485	Feb 14 06:13 PM
Delaet Ingrid	Chief Regulatory Officer	Feb 13 '25	Sale	116.71	1,471	171,674	4,084	Feb 14 06:13 PM
Boyer David W.	Chief Corp. Affairs Officer	Feb 13 '25	Option Exercise	0.00	3,352	0	4,395	Feb 14 06:08 PM
Boyer David W.	Chief Corp. Affairs Officer	Feb 13 '25	Sale	116.74	1,785	208,387	2,854	Feb 14 06:08 PM
BENEVICH ERIC	Chief Commercial Officer	Feb 13 '25	Option Exercise	0.00	4,044	0	45,745	Feb 14 06:03 PM
BENEVICH ERIC	Chief Commercial Officer	Feb 13 '25	Sale	116.73	2,154	251,428	43,784	Feb 14 06:03 PM
ABERNETHY MATT	Chief Financial Officer	Feb 13 '25	Option Exercise	0.00	4,807	0	37,016	Feb 14 06:00 PM
ABERNETHY MATT	Chief Financial Officer	Feb 13 '25	Sale	116.86	2,558	298,923	34,775	Feb 14 06:00 PM
EIRY WYN ROBERTS	Officer	Feb 14 '25	Proposed Sale	115.04	500	57,521		Feb 14 04:12 PM
STEPHEN A SHERWIN	Director	Feb 13 '25	Proposed Sale	117.18	13,831	1,620,717		Feb 13 04:38 PM
MATTHEW ABERNETHY	Officer	Feb 13 '25	Proposed Sale	117.18	1,352	158,427		Feb 13 04:38 PM
MATTHEW C ABERNETHY	Officer	Feb 13 '25	Proposed Sale	117.18	1,206	141,319		Feb 13 04:37 PM
KEVIN CHARLES GORMAN	Director	Feb 13 '25	Proposed Sale	117.18	3,012	352,946		Feb 13 04:37 PM
KYLE W GANO	Officer	Feb 13 '25	Proposed Sale	117.18	1,206	141,319		Feb 13 04:37 PM
JULIE SMITH COOKE	Officer	Feb 13 '25	Proposed Sale	117.18	755	88,471		Feb 13 04:37 PM
ERIC S BENEVICH	Officer	Feb 13 '25	Proposed Sale	117.18	1,056	123,742		Feb 13 04:36 PM
JUDE ONYIA	Officer	Feb 13 '25	Proposed Sale	117.18	1,447	169,559		Feb 13 04:36 PM
INGRID DELAET	Officer	Feb 13 '25	Proposed Sale	117.18	755	88,471		Feb 13 04:36 PM
DAVID WARREN BOYER	Officer	Feb 13 '25	Proposed Sale	117.18	830	97,259		Feb 13 04:35 PM
DARIN LIPPOLDT	Officer	Feb 13 '25	Proposed Sale	117.18	1,086	127,257		Feb 13 04:35 PM
EIRY WYN ROBERTS	Officer	Feb 13 '25	Proposed Sale	117.18	604	70,777		Feb 13 04:35 PM
EIRY ROBERTS	Officer	Feb 13 '25	Proposed Sale	117.18	1,114	130,539		Feb 13 04:34 PM
DARIN LIPPOLDT	Officer	Feb 13 '25	Proposed Sale	117.18	1,098	128,664		Feb 13 04:34 PM
ERIC BENEVICH	Officer	Feb 13 '25	Proposed Sale	117.18	1,098	128,664		Feb 13 04:34 PM
JUDE ONYIA	Officer	Feb 13 '25	Proposed Sale	117.18	1,432	167,802		Feb 13 04:34 PM
INGRID DELAET	Officer	Feb 13 '25	Proposed Sale	117.18	716	83,901		Feb 13 04:33 PM
DAVID WARREN BOYER	Officer	Feb 13 '25	Proposed Sale	117.18	955	111,907		Feb 13 04:33 PM
JULIE COOKE	Officer	Feb 13 '25	Proposed Sale	117.18	796	93,275		Feb 13 04:33 PM
KYLE GANO	Officer	Feb 13 '25	Proposed Sale	117.18	1,352	158,427		Feb 13 04:32 PM
Kevin Charles Gorman	Director	Feb 13 '25	Proposed Sale	117.18	2,832	331,854		Feb 13 04:31 PM
Cooke Julie	Chief Human Resources Officer	Feb 08 '25	Option Exercise	0.00	1,329	0	19,531	Feb 12 07:00 PM
Cooke Julie	Chief Human Resources Officer	Feb 10 '25	Sale	118.28	700	82,792	18,831	Feb 12 07:00 PM
GORMAN KEVIN CHARLES	Director	Feb 08 '25	Option Exercise	0.00	4,318	0	521,348	Feb 12 06:56 PM
GORMAN KEVIN CHARLES	Director	Feb 10 '25	Sale	118.37	2,274	269,167	519,074	Feb 12 06:56 PM
ROBERTS EIRY	Chief Medical Officer	Feb 08 '25	Option Exercise	0.00	1,860	0	34,233	Feb 12 06:52 PM
ROBERTS EIRY	Chief Medical Officer	Feb 10 '25	Sale	118.22	980	115,853	33,253	Feb 12 06:52 PM
Lippoldt Darin	Chief Legal Officer	Feb 08 '25	Option Exercise	0.00	1,727	0	42,590	Feb 12 06:49 PM
Lippoldt Darin	Chief Legal Officer	Feb 10 '25	Sale	118.25	911	107,727	41,679	Feb 12 06:49 PM
Gano Kyle	Chief Executive Officer	Feb 08 '25	Option Exercise	0.00	1,860	0	138,638	Feb 12 06:48 PM
Gano Kyle	Chief Executive Officer	Feb 10 '25	Sale	118.39	980	116,020	137,658	Feb 12 06:48 PM
Boyer David W.	Chief Corp. Affairs Officer	Feb 08 '25	Option Exercise	0.00	1,329	0	2,698	Feb 12 06:46 PM
Boyer David W.	Chief Corp. Affairs Officer	Feb 10 '25	Sale	118.31	700	82,820	1,998	Feb 12 06:46 PM
BENEVICH ERIC	Chief Commercial Officer	Feb 08 '25	Option Exercise	0.00	1,860	0	43,779	Feb 12 06:44 PM
BENEVICH ERIC	Chief Commercial Officer	Feb 10 '25	Sale	118.31	980	115,940	42,799	Feb 12 06:44 PM
ABERNETHY MATT	Chief Financial Officer	Feb 08 '25	Option Exercise	0.00	1,860	0	34,541	Feb 12 06:41 PM
ABERNETHY MATT	Chief Financial Officer	Feb 10 '25	Sale	118.27	980	115,909	33,561	Feb 12 06:41 PM
KYLE W GANO	Officer	Feb 10 '25	Proposed Sale	122.62	980	120,168		Feb 10 04:33 PM
JULIE SMITH COOKE	Officer	Feb 10 '25	Proposed Sale	122.62	700	85,834		Feb 10 04:33 PM
DAVID WARREN BOYER	Officer	Feb 10 '25	Proposed Sale	122.62	700	85,834		Feb 10 04:33 PM
ERIC BENEVICH	Officer	Feb 10 '25	Proposed Sale	122.62	980	120,168		Feb 10 04:32 PM
KEVIN CHARLES GORMAN	Director	Feb 10 '25	Proposed Sale	122.62	2,274	278,838		Feb 10 04:32 PM
DARIN LIPPOLDT	Officer	Feb 10 '25	Proposed Sale	122.62	911	111,707		Feb 10 04:32 PM
EIRY WYN ROBERTS	Officer	Feb 10 '25	Proposed Sale	122.62	980	120,168		Feb 10 04:31 PM
MATTHEW C ABERNETHY	Officer	Feb 10 '25	Proposed Sale	122.62	980	120,168		Feb 10 04:30 PM
Cooke Julie	Chief Human Resources Officer	Jan 31 '25	Option Exercise	0.00	1,740	0	19,942	Feb 04 06:05 PM
Cooke Julie	Chief Human Resources Officer	Jan 31 '25	Sale	152.89	1,740	266,025	18,202	Feb 04 06:05 PM
GORMAN KEVIN CHARLES	Director	Jan 31 '25	Option Exercise	0.00	5,141	0	519,737	Feb 04 05:58 PM
GORMAN KEVIN CHARLES	Director	Jan 31 '25	Sale	152.92	2,707	413,967	517,030	Feb 04 05:58 PM
ROBERTS EIRY	Chief Medical Officer	Jan 31 '25	Option Exercise	0.00	2,769	0	33,830	Feb 04 05:54 PM
ROBERTS EIRY	Chief Medical Officer	Jan 31 '25	Sale	152.80	1,457	222,636	32,373	Feb 04 05:54 PM
Onyia Jude	Chief Scientific Officer	Jan 31 '25	Option Exercise	0.00	238	0	15,687	Feb 04 05:51 PM
Onyia Jude	Chief Scientific Officer	Jan 31 '25	Sale	152.97	126	19,274	15,561	Feb 04 05:51 PM
Lippoldt Darin	Chief Legal Officer	Jan 31 '25	Option Exercise	0.00	2,373	0	42,113	Feb 04 05:49 PM
Lippoldt Darin	Chief Legal Officer	Jan 31 '25	Sale	152.91	1,250	191,133	40,863	Feb 04 05:49 PM
Gano Kyle	Chief Executive Officer	Jan 31 '25	Option Exercise	0.00	2,927	0	138,319	Feb 04 05:47 PM
Gano Kyle	Chief Executive Officer	Jan 31 '25	Sale	152.87	1,541	235,577	136,778	Feb 04 05:47 PM
Delaet Ingrid	Chief Regulatory Officer	Jan 31 '25	Option Exercise	0.00	801	0	3,308	Feb 04 05:45 PM
Delaet Ingrid	Chief Regulatory Officer	Feb 03 '25	Option Exercise	0.00	1,179	0	4,065	Feb 04 05:45 PM
Delaet Ingrid	Chief Regulatory Officer	Feb 03 '25	Sale	149.29	623	93,008	3,442	Feb 04 05:45 PM
Delaet Ingrid	Chief Regulatory Officer	Jan 31 '25	Sale	153.05	422	64,587	2,886	Feb 04 05:45 PM
Boyer David W.	Chief Corp. Affairs Officer	Jan 31 '25	Option Exercise	0.00	2,096	0	2,473	Feb 04 05:42 PM
Boyer David W.	Chief Corp. Affairs Officer	Jan 31 '25	Sale	152.94	1,104	168,849	1,369	Feb 04 05:42 PM
BENEVICH ERIC	Chief Commercial Officer	Jan 31 '25	Option Exercise	0.00	2,294	0	43,126	Feb 04 05:35 PM
BENEVICH ERIC	Chief Commercial Officer	Jan 31 '25	Sale	152.94	1,207	184,599	41,919	Feb 04 05:35 PM
ABERNETHY MATT	Chief Financial Officer	Jan 31 '25	Option Exercise	0.00	2,436	0	33,964	Feb 04 05:31 PM
ABERNETHY MATT	Chief Financial Officer	Jan 31 '25	Sale	152.87	1,283	196,136	32,681	Feb 04 05:31 PM
INGRID DELAET	Officer	Feb 03 '25	Proposed Sale	151.82	623	94,584		Feb 03 04:19 PM
JULIE COOKE	Officer	Jan 31 '25	Proposed Sale	153.29	824	126,311		Jan 31 04:34 PM
KEVIN CHARLES GORMAN	Director	Jan 31 '25	Proposed Sale	153.29	2,707	414,956		Jan 31 04:33 PM
EIRY WYN ROBERTS	Officer	Jan 31 '25	Proposed Sale	153.29	1,457	223,344		Jan 31 04:32 PM
INGRID DELAET	Officer	Jan 31 '25	Proposed Sale	153.29	422	64,688		Jan 31 04:32 PM
KYLE GANO	Director	Jan 31 '25	Proposed Sale	153.29	1,541	236,220		Jan 31 04:31 PM
MATTHEW C ABERNETHY	Officer	Jan 31 '25	Proposed Sale	153.29	1,283	196,671		Jan 31 04:29 PM
ERIC BENEVICH	Officer	Jan 31 '25	Proposed Sale	153.29	1,207	185,021		Jan 31 04:29 PM
DAVID WARREN BOYER	Officer	Jan 31 '25	Proposed Sale	153.29	1,104	169,232		Jan 31 04:28 PM
DARIN LIPPOLDT	Officer	Jan 31 '25	Proposed Sale	153.29	1,250	191,612		Jan 31 04:28 PM

BIIB

Biogen Inc

NBIX

Neurocrine Biosciences, Inc

Upgrade your FINVIZ experience